Tatva Chintan Pharma Chem Limited has informed the Exchange about Appointment of Secretarial Auditor, Cost Auditor and Internal Auditor
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem's board approved audited financial results for Q4 and FY ended 31 March 2025, along with a final dividend of Rs. 1 (10%) per equity share for FY25, subject to shareholder approval. Consolidated revenue from operations for FY25 stood at Rs. 3,827.14 million, while net profit fell sharply to Rs. 75.79 million from Rs. 435.68 million in FY24, dragging EPS down to Rs. 4.11 from Rs. 13.26. The board also appointed M/s. TNT & Associates as Secretarial Auditor for five years (FY26–FY30), M/s. Zarna Thakar & Associates as Cost Auditor for FY26, and RSM Astute Consultech Private Limited as Internal Auditor for FY26. The statutory auditor (NDJ & Co.) issued an unmodified opinion on both standalone and consolidated results.
The steep year-on-year drop in profit is a key concern for shareholders despite the continuity in dividend and stable auditor appointments. The new auditor appointments are routine compliance matters and unlikely to materially affect the stock, though the weak FY25 earnings print may weigh on short-term sentiment.